홈 › 미만성 거대 B세포 림프종 › 미시간
미시간의 미만성 거대 B세포 림프종 임상 시험
미만성 거대 B세포 림프종 관련 연구 17개가 미시간 내 여러 지역에서 참여자를 모집하고 있습니다.
미시간의 도시
공식 연구 텍스트(영어)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9545), Ann Arbor
- Karmanos Cancer Institute ( Site 0174), Detroit
- Corewell Health ( Site 0130), Grand Rapids
- 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 13. 업데이트됨 · NCT06717347Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Corewell Health, Grand Rapids
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 10. 업데이트됨 · NCT06806033Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- OSF Saint Francis Hospital and Medical Group, Escanaba
- Schoolcraft Memorial Hospital, Manistique
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 9. 업데이트됨 · NCT06649812Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
- Karmanos Cancer Center (Wayne State University), Detroit
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 11. 5. 업데이트됨 · NCT05852717A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
- Henry Ford Health System, Detroit
- Cancer and Hematology Centers of Western Michigan, Grand Rapids
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT06091865A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Michigan Comprehensive Cancer Center, Ann Arbor
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 11. 4. 업데이트됨 · NCT07101328A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
- Corewell Health ( Site 0162), Grand Rapids
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 11. 3. 업데이트됨 · NCT05139017Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
- Research Site, Detroit
피험자 모집 중2상
65세 ~ 99세 · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT05952024Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Corewell Health ( Site 1001), Grand Rapids
피험자 모집 중1/2상
6 Months – 25 Years · 모든 성별 · 2026. 10. 30. 업데이트됨 · NCT06395103Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- Trinity Health IHA Medical Group Hematology Oncology - Brighton, Brighton
- Trinity Health Medical Center - Brighton, Brighton
- 외 12개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 28. 업데이트됨 · NCT05890352Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy
- University of Michigan Rogel Cancer Center, Ann Arbor
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 23. 업데이트됨 · NCT07892027A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- START Midwest, Grand Rapids
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 15. 업데이트됨 · NCT07424833Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Bronson Battle Creek, Battle Creek
- Henry Ford Macomb Hospital-Clinton Township, Clinton Township
- Henry Ford Medical Center-Fairlane, Dearborn
- 외 15개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 15. 업데이트됨 · NCT05633615A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
- University of Michigan, Ann Arbor
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 9. 업데이트됨 · NCT07195916A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Karmanos Cancer Institute, Detroit
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 5. 업데이트됨 · NCT05006716Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Corewell Health, Grand Rapids
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT05826535DALY II USA/ MB-CART2019.1 for DLBCL
- University of Michigan, Ann Arbor
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 7. 13. 업데이트됨 · NCT04792489ClinicalTrials.gov 출처, 2026. 11. 15. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.